Postnatal Deletion of the Type II Transforming Growth Factor-β Receptor in Smooth Muscle Cells Causes Severe Aortopathy in Mice

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 35, Issue 12, 2015, Pages 2647-2656

  Hu, Jie Hong ^a   Wei, Hao ^a   Jaffe, Mia ^a   Airhart, Nathan ^a   Du, Liang ^a   Angelov, Stoyan N ^a   Yan, James ^a   Allen, Julie K ^a   Kang, Inkyung ^b   Wight, Thomas N ^b   Fox, Kate ^a   Smith, Alexandra ^a   Enstrom, Rachel ^a   Dichek, David A ^a  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b BENAROYA RESEARCH INSTITUTE   (United States)

Author keywords

Alleles; aortic aneurysm; homeostasis; tamoxifen; transforming growth factors

Indexed keywords

BETA GALACTOSIDASE; CRE RECOMBINASE; MESSENGER RNA; PROTEOGLYCAN; TAMOXIFEN; TRANSFORMING GROWTH FACTOR BETA RECEPTOR 2; ELASTIN; PROTEIN SERINE THREONINE KINASE; TGFB1 PROTEIN, MOUSE; TRANSFORMING GROWTH FACTOR BETA RECEPTOR; TRANSFORMING GROWTH FACTOR BETA1; TRANSFORMING GROWTH FACTOR-BETA TYPE II RECEPTOR;

ALLELE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA DILATION; AORTA DISEASE; AORTA DISSECTION; AORTA HEMORRHAGE; AORTA ULCER; ARTERIAL WALL THICKNESS; ARTICLE; ASCENDING AORTA; CONTROLLED STUDY; ELASTOLYSIS; GENE DELETION; GENE EXPRESSION; GENE REARRANGEMENT; HEMATOMA; HOMOZYGOSITY; IN VITRO STUDY; IN VIVO STUDY; LOXP SITE; MACROPHAGE; MOUSE; NONHUMAN; PERINATAL PERIOD; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; AGE; ANIMAL; AORTA; CELL PROLIFERATION; DEFICIENCY; DRUG EFFECTS; EXTRACELLULAR MATRIX; GENE EXPRESSION REGULATION; GENETIC PREDISPOSITION; GENETICS; KNOCKOUT MOUSE; METABOLISM; PATHOLOGY; PHENOTYPE; SMOOTH MUSCLE CELL; VASCULAR SMOOTH MUSCLE;

AGE FACTORS; ANIMALS; AORTA; AORTIC DISEASES; CELL PROLIFERATION; ELASTIN; EXTRACELLULAR MATRIX; GENE EXPRESSION REGULATION; GENETIC PREDISPOSITION TO DISEASE; MACROPHAGES; MICE, KNOCKOUT; MUSCLE, SMOOTH, VASCULAR; MYOCYTES, SMOOTH MUSCLE; PHENOTYPE; PROTEIN-SERINE-THREONINE KINASES; RECEPTORS, TRANSFORMING GROWTH FACTOR BETA; RNA, MESSENGER; SIGNAL TRANSDUCTION; TRANSFORMING GROWTH FACTOR BETA1;

EID: 84948111046     PISSN: 10795642     EISSN: 15244636     Source Type: Journal    
DOI: 10.1161/ATVBAHA.115.306573     Document Type: Article

References (53)

1. Björkerud S. Effects of transforming growth factor-beta 1 on human arterial smooth muscle cells in vitro. Arterioscler Thromb. 1991;11:892-902.
2. Owens GK, Kumar MS, Wamhoff BR. Molecular regulation of vascular smooth muscle cell differentiation in development and disease. Physiol Rev. 2004;84:767-801. doi: 10.1152/physrev.00041.2003.
3. Saltis J, Agrotis A, Bobik A. Regulation and interactions of transforming growth factor-beta with cardiovascular cells: implications for development and disease. Clin Exp Pharmacol Physiol. 1996;23:193-200.
4. Goumans MJ, Liu Z, ten Dijke P. TGF-beta signaling in vascular biology and dysfunction. Cell Res. 2009;19:116-127. doi: 10.1038/cr.2008.326.
5. Sinha S, Hoofnagle MH, Kingston PA, McCanna ME, Owens GK. Transforming growth factor-beta1 signaling contributes to development of smooth muscle cells from embryonic stem cells. Am J Physiol Cell Physiol. 2004;287:C1560-C1568. doi: 10.1152/ajpcell.00221.2004.
6. Davis-Dusenbery BN, Chan MC, Reno KE, Weisman AS, Layne MD, Lagna G, Hata A. Down-regulation of Kruppel-like factor-4 (KLF4) by microRNA-143/145 is critical for modulation of vascular smooth muscle cell phenotype by transforming growth factor-beta and bone morphogenetic protein 4. J Biol Chem. 2011;286:28097-28110. doi: 10.1074/jbc. M111.236950.
7. Frutkin AD, Shi H, Otsuka G, Leveén P, Karlsson S, Dichek DA. A critical developmental role for tgfbr2 in myogenic cell lineages is revealed in mice expressing SM22-Cre, not SMMHC-Cre. J Mol Cell Cardiol. 2006;41:724-731. doi: 10.1016/j.yjmcc.2006.06.067.
8. Carvalho RL, Itoh F, Goumans MJ, Lebrin F, Kato M, Takahashi S, Ema M, Itoh S, van Rooijen M, Bertolino P, Ten Dijke P, Mummery CL. Compensatory signalling induced in the yolk sac vasculature by deletion of TGFbeta receptors in mice. J Cell Sci. 2007;120(pt 24):4269-4277. doi: 10.1242/jcs.013169.
9. Langlois D, Hneino M, Bouazza L, Parlakian A, Sasaki T, Bricca G, Li JY. Conditional inactivation of TGF-type II receptor in smooth muscle cells and epicardium causes lethal aortic and cardiac defects. Transgenic Res. 2010;19:1069-1082. doi: 10.1007/s11248-010-9379-4.
10. Jaffe M, Sesti C, Washington IM, Du L, Dronadula N, Chin MT, Stolz DB, Davis EC, Dichek DA. Transforming growth factor-signaling in myogenic cells regulates vascular morphogenesis, differentiation, and matrix synthesis. Arterioscler Thromb Vasc Biol. 2012;32:e1-11. doi: 10.1161/ATVBAHA.111.238410.
11. Schulick AH, Taylor AJ, Zuo W, Qiu CB, Dong G, Woodward RN, Agah R, Roberts AB, Virmani R, Dichek DA. Overexpression of transforming growth factor beta1 in arterial endothelium causes hyperplasia, apoptosis, and cartilaginous metaplasia. Proc Natl Acad Sci USA. 1998;95:6983-6988.
12. Nabel EG, Shum L, Pompili VJ, Yang ZY, San H, Shu HB, Liptay S, Gold L, Gordon D, Derynck R. Direct transfer of transforming growth factor beta 1 gene into arteries stimulates fibrocellular hyperplasia. Proc Natl Acad Sci USA. 1993;90:10759-10763.
13. Otsuka G, Agah R, Frutkin AD, Wight TN, Dichek DA. Transforming growth factor beta 1 induces neointima formation through plasminogen activator inhibitor-1-dependent pathways. Arterioscler Thromb Vasc Biol. 2006;26:737-743. doi: 10.1161/01.ATV.0000201087.23877.e1.
14. Dai J, Losy F, Guinault AM, Pages C, Anegon I, Desgranges P, Becquemin JP, Allaire E. Overexpression of transforming growth factor-beta1 stabilizes already-formed aortic aneurysms: a first approach to induction of functional healing by endovascular gene therapy. Circulation. 2005;112:1008-1015. doi: 10.1161/CIRCULATIONAHA.104.523357.
15. Wang Y, Ait-Oufella H, Herbin O, Bonnin P, Ramkhelawon B, Taleb S, Huang J, Offenstadt G, Combadière C, Rénia L, Johnson JL, Tharaux PL, Tedgui A, Mallat Z. TGF-beta activity protects against inflammatory aortic aneurysm progression and complications in angiotensin II-infused mice. J Clin Invest. 2010;120:422-432. doi: 10.1172/JCI38136.
16. Gomez D, Al Haj Zen A, Borges LF, Philippe M, Gutierrez PS, Jondeau G, Michel JB, Vranckx R. Syndromic and non-syndromic aneurysms of the human ascending aorta share activation of the Smad2 pathway. J Pathol. 2009;218:131-142. doi: 10.1002/path.2516.
17. Habashi JP, Judge DP, Holm TM, et al. Losartan, an AT1 antagonist, prevents aortic aneurysm in a mouse model of Marfan syndrome. Science. 2006;312:117-121. doi: 10.1126/science.1124287.
18. Gallo EM, Loch DC, Habashi JP, et al. Angiotensin II-dependent TGF-signaling contributes to Loeys-Dietz syndrome vascular pathogenesis. J Clin Invest. 2014;124:448-460. doi: 10.1172/JCI69666.
19. Doyle AJ, Doyle JJ, Bessling SL, et al. Mutations in the TGF-repressor SKI cause Shprintzen-Goldberg syndrome with aortic aneurysm. Nat Genet. 2012;44:1249-1254. doi: 10.1038/ng.2421.
20. Lindsay ME, Schepers D, Bolar NA, et al. Loss-of-function mutations in TGFB2 cause a syndromic presentation of thoracic aortic aneurysm. Nat Genet. 2012;44:922-927. doi: 10.1038/ng.2349.
21. Lacro RV, Dietz HC, Wruck LM, et al; Pediatric Heart Network Investigators. Rationale and design of a randomized clinical trial of beta-blocker therapy (atenolol) versus angiotensin II receptor blocker therapy (losartan) in individuals with Marfan syndrome. Am Heart J. 2007;154:624-631. doi: 10.1016/j.ahj.2007.06.024.
22. Brooke BS, Habashi JP, Judge DP, Patel N, Loeys B, Dietz HC III. Angiotensin II blockade and aortic-root dilation in Marfan's syndrome. N Engl J Med. 2008;358:2787-2795. doi: 10.1056/NEJMoa0706585.
23. Lacro RV, Dietz HC, Sleeper LA, et al; Pediatric Heart Network Investigators. Atenolol versus losartan in children and young adults with Marfan's syndrome. N Engl J Med. 2014;371:2061-2071. doi: 10.1056/NEJMoa1404731.
24. Li W, Li Q, Jiao Y, Qin L, Ali R, Zhou J, Ferruzzi J, Kim RW, Geirsson A, Dietz HC, Offermanns S, Humphrey JD, Tellides G. Tgfbr2 disruption in postnatal smooth muscle impairs aortic wall homeostasis. J Clin Invest. 2014;124:755-767. doi: 10.1172/JCI69942.
25. Leveén P, Larsson J, Ehinger M, Cilio CM, Sundler M, Sjöstrand LJ, Holmdahl R, Karlsson S. Induced disruption of the transforming growth factor beta type II receptor gene in mice causes a lethal inflammatory disorder that is transplantable. Blood. 2002;100:560-568.
26. Wendling O, Bornert JM, Chambon P, Metzger D. Efficient temporallycontrolled targeted mutagenesis in smooth muscle cells of the adult mouse. Genesis. 2009;47:14-18. doi: 10.1002/dvg.20448.
27. Wirth A, Benyó Z, Lukasova M, Leutgeb B, Wettschureck N, Gorbey S, Orsy P, Horváth B, Maser-Gluth C, Greiner E, Lemmer B, Schütz G, Gutkind JS, Offermanns S. G12-G13-LARG-mediated signaling in vascular smooth muscle is required for salt-induced hypertension. Nat Med. 2008;14:64-68. doi: 10.1038/nm1666.
28. Pérez GJ. Dual effect of tamoxifen on arterial KCa channels does not depend on the presence of the beta1 subunit. J Biol Chem. 2005;280:21739-21747. doi: 10.1074/jbc.M413953200.
29. Leung HS, Yung LM, Leung FP, Yao X, Chen ZY, Ko WH, Laher I, Huang Y. Tamoxifen dilates porcine coronary arteries: roles for nitric oxide and ouabain-sensitive mechanisms. Br J Pharmacol. 2006;149:703-711. doi: 10.1038/sj.bjp.0706921.
30. Ning N, Lin G, Lue TF, Lin CS. Effects of estrogen, raloxifene, and levormeloxifene on the expression of Rho-kinase signaling molecules in urethral smooth muscle cells. Urology. 2010;76:1517.e6-1517.11. doi: 10.1016/j.urology.2010.07.470.
31. Dellê H, Rocha JR, Cavaglieri RC, Vieira JM Jr, Malheiros DM, Noronha IL. Antifibrotic effect of tamoxifen in a model of progressive renal disease. J Am Soc Nephrol. 2012;23:37-48. doi: 10.1681/ASN.2011010046.
32. Savolainen-Peltonen H, Luoto NM, Kangas L, Haÿry P. Selective estrogen receptor modulators prevent neointima formation after vascular injury. Mol Cell Endocrinol. 2004;227:9-20. doi: 10.1016/j.mce.2004.08.004.
33. Schönherr E, Järvelaïnen HT, Sandell LJ, Wight TN. Effects of plateletderived growth factor and transforming growth factor-beta 1 on the synthesis of a large versican-like chondroitin sulfate proteoglycan by arterial smooth muscle cells. J Biol Chem. 1991;266:17640-17647.
34. Wight TN, Kang I, Merrilees MJ. Versican and the control of inflammation. Matrix Biol. 2014;35:152-161. doi: 10.1016/j.matbio.2014.01.015.
35. Kang I, Barth JL, Sproul EP, Yoon DW, Workman GA, Braun KR, Argraves WS, Wight TN. Expression of V3 Versican by rat arterial smooth muscle cells promotes differentiated and anti-inflammatory phenotypes. J Biol Chem. 2015;290:21629-21641. doi: 10.1074/jbc.M115.657486.
36. Pannu H, Tran-Fadulu V, Papke CL, Scherer S, Liu Y, Presley C, Guo D, Estrera AL, Safi HJ, Brasier AR, Vick GW, Marian AJ, Raman CS, Buja LM, Milewicz DM. MYH11 mutations result in a distinct vascular pathology driven by insulin-like growth factor 1 and angiotensin II. Hum Mol Genet. 2007;16:2453-2462. doi: 10.1093/hmg/ddm201.
37. Lee S, Agah R, Xiao M, Frutkin AD, Kremen M, Shi H, Dichek DA. Regulated transgene expression in vascular smooth muscle. Circ Res. 2005;97:e85-e85.
38. Gomez D, Owens GK. Smooth muscle cell phenotypic switching in atherosclerosis. Cardiovasc Res. 2012;95:156-164. doi: 10.1093/cvr/cvs115.
39. Shankman LS, Gomez D, Cherepanova OA, Salmon M, Alencar GF, Haskins RM, Swiatlowska P, Newman AA, Greene ES, Straub AC, Isakson B, Randolph GJ, Owens GK. KLF4-dependent phenotypic modulation of smooth muscle cells has a key role in atherosclerotic plaque pathogenesis. Nat Med. 2015;21:628-637. doi: 10.1038/nm.3866.
40. Herring BP, Hoggatt AM, Burlak C, Offermanns S. Previously differentiated medial vascular smooth muscle cells contribute to neointima formation following vascular injury. Vasc Cell. 2014;6:21. doi: 10.1186/2045-824X-6-21.
41. McCaffrey TA, Du B, Consigli S, Szabo P, Bray PJ, Hartner L, Weksler BB, Sanborn TA, Bergman G, Bush HL Jr. Genomic instability in the type II TGF-beta1 receptor gene in atherosclerotic and restenotic vascular cells. J Clin Invest. 1997;100:2182-2188. doi: 10.1172/JCI119754.
42. Loeys BL, Chen J, Neptune ER, et al. A syndrome of altered cardiovascular, craniofacial, neurocognitive and skeletal development caused by mutations in TGFBR1 or TGFBR2. Nat Genet. 2005;37:275-281. doi: 10.1038/ng1511.
43. Gomez D, Coyet A, Ollivier V, Jeunemaitre X, Jondeau G, Michel JB, Vranckx R. Epigenetic control of vascular smooth muscle cells in Marfan and non-Marfan thoracic aortic aneurysms. Cardiovasc Res. 2011;89:446-456. doi: 10.1093/cvr/cvq291.
44. Akhurst RJ. The paradoxical TGF-vasculopathies. Nat Genet. 2012;44:838-839. doi: 10.1038/ng.2366.
45. Lindsay ME, Dietz HC. Lessons on the pathogenesis of aneurysm from heritable conditions. Nature. 2011;473:308-316. doi: 10.1038/nature10145.
46. Frutkin AD, Otsuka G, Stempien-Otero A, Sesti C, Du L, Jaffe M, Dichek HL, Pennington CJ, Edwards DR, Nieves-Cintrón M, Minter D, Preusch M, Hu JH, Marie JC, Dichek DA. TGF-[beta]1 limits plaque growth, stabilizes plaque structure, and prevents aortic dilation in apolipoprotein E-null mice. Arterioscler Thromb Vasc Biol. 2009;29:1251-1257. doi: 10.1161/ATVBAHA.109.186593.
47. Lacro RV, Dietz HC, Mahony L. Atenolol versus Losartan in Marfan's syndrome. N Engl J Med. 2015;372:980-981. doi: 10.1056/NEJMc1500128.
48. Cook JR, Clayton NP, Carta L, Galatioto J, Chiu E, Smaldone S, Nelson CA, Cheng SH, Wentworth BM, Ramirez F. Dimorphic effects of transforming growth factor-signaling during aortic aneurysm progression in mice suggest a combinatorial therapy for Marfan syndrome. Arterioscler Thromb Vasc Biol. 2015;35:911-917. doi: 10.1161/ATVBAHA.114.305150.
49. Iwata J, Hacia JG, Suzuki A, Sanchez-Lara PA, Urata M, Chai Y. Modulation of noncanonical TGF-signaling prevents cleft palate in Tgfbr2 mutant mice. J Clin Invest. 2012;122:873-885. doi: 10.1172/JCI61498.
50. Boileau C, Guo DC, Hanna N, et al; National Heart, Lung, and Blood Institute (NHLBI) Go Exome Sequencing Project. TGFB2 mutations cause familial thoracic aortic aneurysms and dissections associated with mild systemic features of Marfan syndrome. Nat Genet. 2012;44:916-921. doi: 10.1038/ng.2348.
51. Majesky MW. Developmental basis of vascular smooth muscle diversity. Arterioscler Thromb Vasc Biol. 2007;27:1248-1258. doi: 10.1161/ATVBAHA.107.141069.
52. Mizuguchi T, Collod-Beroud G, Akiyama T, et al. Heterozygous TGFBR2 mutations in Marfan syndrome. Nat Genet. 2004;36:855-860. doi: 10.1038/ng1392.
53. Horbelt D, Guo G, Robinson PN, Knaus P. Quantitative analysis of TGFBR2 mutations in Marfan-syndrome-related disorders suggests a correlation between phenotypic severity and Smad signaling activity. J Cell Sci. 2010;123(pt 24):4340-4350. doi: 10.1242/jcs.074773.